RxDoctor Payments Data

Cuie Qiu, MD

Neurology · Pearland, TXNPI 1972738045

Payments from drug & device makers

$9,432in general payments, 2019–2025

Across 495 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$791
  • Novartis$775
  • Argenx US, Inc.$559
  • UCB, Inc.$519
  • Pfizer$409
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$390%
  • Food & beverage$9,393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)69$1,323
Amgen44$791
Novartis40$775
Argenx US, Inc.14$559
UCB, Inc.20$519
Pfizer23$409
Teva Pharmaceuticals USA, Inc.26$390
Sunovion Pharmaceuticals Inc.28$342
Radius Health, Inc.15$252
Lilly USA, LLC15$251
AstraZeneca(2 entities)11$213
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$198
EMD Serono, Inc.10$181
IBSA Pharma Inc.12$179
Otsuka America Pharmaceutical, Inc.10$172
SK Life Science, Inc.6$162
Acorda Therapeutics, Inc3$142
Novo Nordisk8$139
Exact Sciences7$135
Supernus Pharmaceuticals, Inc.7$112
Eisai Inc.7$111
Lundbeck LLC4$106
Aimmune Therapeutics, Inc.5$105
Avanir Pharmaceuticals, Inc.6$94
Takeda Pharmaceuticals U.S.A., Inc.4$90
Sanofi-aventis U.S. LLC4$90
Grifols USA, LLC5$88
Abbott5$87
Axsome Therapeutics, Inc.4$76
Corcept Therapeutics4$74
Neurocrine Biosciences, Inc.3$73
Sanofi4$72
Amarin Pharma, Inc.3$69
Biogen3$64
Catalyst Pharmaceuticals, Inc.3$56
Biohaven Pharmaceutical Holding Company Ltd.3$48
Assertio Therapeutics, Inc.3$47
Biohaven Pharmaceuticals, Inc.2$46
Vanda Pharmaceuticals Inc.2$46
GSK2$44
Dexcom, Inc.2$42
Merck3$41
Acadia Pharmaceuticals Inc2$38
Medtronic(2 entities)2$36
Upsher-smith Laboratories LLC2$35
Vertical Pharmaceuticals, LLC2$34
Irhythm Technologies, Inc.1$33
Amneal Pharmaceuticals LLC2$30
Adamas Pharmaceuticals, Inc.2$29
Springworks Therapeutics, Inc.1$28
Insulet Corporation1$24
TG Therapeutics, Inc.1$23
Nestle Healthcare Nutrition Inc.1$22
Viiv Healthcare Company1$22
Alvogen Inc1$22
Avvisto Therapeutics, LLC1$21
Kyowa Kirin, Inc.1$20
Bausch Health US, LLC1$19
Azurity Pharmaceuticals, Inc.1$19
GE HealthCare1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,432 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$180,670
Medicare patients
356
Services billed
6,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5016$142,444
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5015$66,164
Gamunex-CImmune Globul G/Gly/Iga Avg 4629$58,927
UbrelvyUbrogepant27$27,662
Nurtec OdtRimegepant Sulfate12$19,205
Memantine Hcl287$15,140
Emgality PenGalcanezumab-Gnlm11$14,176
Ajovy AutoinjectorFremanezumab-Vfrm11$7,934
Gabapentin381$5,916
Methazolamide17$4,615
Carbamazepine ErCarbamazepine18$3,411
Pyridostigmine Bromide29$3,268
Carbidopa-LevodopaCarbidopa/Levodopa76$2,974
Sertraline Hcl318$2,787
Acetazolamide69$2,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$88$58,92729 claims
AbbVieUbrelvy$1,323$27,66227 claims
PfizerNurtec Odt$409$19,20512 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$30$3,94841 claims
Upsher-smith Laboratories LLCTopiramate$35$1,08594 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →